The treatment, known as CD24Fc, is administered intravenously along with standard-of-care. Phase 3 trial results for the drug showed it reduced the risk of death or respiratory failure by more than 50 percent in hospitalized COVID-19 patients who required oxygen. Comprehensive results will soon be submitted for publication in a peer-reviewed medical journal, Merck said in a news release.
Merck said the deal, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act, is expected to close by the end of 2020. Upon the acquisition’s close, Merck aims to ramp up production of CD24Fc in anticipation of its FDA emergency authorization.
More articles on pharmacy:
AstraZeneca says vaccine is up to 90% effective in preventing COVID-19
Walgreens CFO: I’m not worried about Amazon’s online pharmacy
Regeneron wins EUA for COVID-19 antibody cocktail
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.